ATC Group: J01FA06 Roxithromycin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J01FA06 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J01 Antibacterials for systemic use
3 J01F Macrolides, lincosamides and streptogramins
4 J01FA Macrolides
5 J01FA06 Roxithromycin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.3 g

Active ingredients in J01FA06

Active Ingredient Description
Roxithromycin

Roxithromycin is a semi-synthetic macrolide antibiotic. Roxithromycin is bacteriostatic at low concentrations and bactericidal at high concentrations. It binds to the 50S subunit of the 70S ribosome, thereby disrupting bacterial protein synthesis.

Medicines in this ATC group

Australia (AU)

Austria (AT)

Cyprus (CY)

France (FR)

Germany (DE)

Israel (IL)

Japan (JP)

Malta (MT)

New Zealand (NZ)

Poland (PL)

Singapore (SG)

South Africa (ZA)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.